Eligo Bioscience, a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.
The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.
The UK has unveiled £34.5 million ($42.8 million) in funding for four hubs dedicated to the development of vaccines for diseases with epidemic potential in low- and middle-income countries (LMICs).
Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and...
Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...
TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, has been awarded a £995,000 grant from Innovate UK.
HexisLab, a UK biotech company, has secured a £490,000 funding grant from Innovate UK to develop a scale-up manufacturing process for its novel sustainable and green ingredients.
A well-funded and appropriately rewarded biotech ecosystem is needed for the next generation of antibacterials to reach the clinic and beyond, according to BIO’s State of Innovation in Antibacterial Therapeutics report.
EQT VIII Fund set to acquire majority interest in plasmid DNA supplier Aldevron, announces investments to support the expansion of its production capacity.
The US FDA is faced with lapsed funding appropriations as the US government shutdown continues, causing the agency to focus on addressing immediate threats to consumer safety.